Pattern and treatment of Parkinson’s disease at different health care levels in Bangladesh: a hospital based survey

Sharmin Sultana; M. Lokman Hossain; M. Nazma Parvin

doi:10.18203/issn.2454-2156.IntJSciRep20201269

Authors

Sharmin Sultana Pharmacy Discipline, Life Science School, Khulna University, Khulna
M. Lokman Hossain Department of Pharmacy, Stamford University Bangladesh, Dhaka
M. Nazma Parvin Department of Pharmacy, Stamford University Bangladesh, Dhaka

DOI:

https://doi.org/10.18203/issn.2454-2156.IntJSciRep20201269

Keywords:

Parkinson’s disease, Motor system disorder, Tremor, Rigidity, Bradykinesia, Drugs

Abstract

Background: Parkinson’s disease (PD) is a condition in which part of the brain becomes progressively damaged over many years. This study represents the pattern of Parkinson’s disease and help to identify various drugs which are being used at different health care levels in Bangladesh.

Methods: Cross-sectional technique was applied as study design in this research work. We accessed the patients with formulated questionnaire of the Department of Neuroscience of National Institute of Neurosciences and Hospital, Dhaka Medical College and Hospital and Bangabandhu Sheikh Mujib Medical University (BSMMU) for data collection from January 2017 to August 2019. 100 patients were selected in the ages between 25-80 years, among them 66 were male and 34 females.

Results: A total number of 100 Parkinson’s disease patients (male 66%, female 34%) were recruited for this study. Genetic factor (56%) is the main cause of PD found in this study. Among various symptoms, the prominent symptoms were voice disorders (96%), slowness of movement (90%), mask-like face expression (86%), tremor (80%), sensory and sleep difficulties (78%), excessive sweating (60%) and insomnia (56%). It was observed that along with physiotherapy, drugs used to manage PD were levodopa (14%), carbamazepine (12%), quetiapine (12%), haloperidol (11%), pramipexole (10%), trihexyphenidyl HCl (10%), carbidopa (8%), amlodipine (8%) and clonazepam (8%).

Conclusions: Disgrace exists in the personal life and social context of the PD patients which also unfavourably affects their psychosocial aspects of life. Our population-based data provide evidence for a protective effect of Parkinson’s disease in our country.

Metrics

Metrics Loading ...

References

Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol. 2006;5(6):525-35.

Clarke CE. Neuroprotection and pharmacotherapy for motor symptoms in Parkinson’s disease. Lancet Neurol. 2004;3:466-74.

Sveinbjornsdottir S. The clinical symptoms of Parkinson's disease. J Neurochem. 2016;139:318-24.

Pearce JM. Aspects of the history of Parkinson's disease. J Neurol Neurosurg Psychiatry. 1989;6:6-10.

Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson’s disease: treatment guidelines. Neurology. 2001;56(11):1-88.

Chrischilles EA, Rubenstein LM, Voelker MD, Wallace RB, Rodnitzky RL. The health burdens of Parkinson's disease. Mov Disord. 1998;13(3):406-13.

Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson's disease: a systematic review and meta-analysis. Mov Disord. 2014;29(13):1583-90.

Huse DM, Schulman K, Orsini L, Haley CJ, Kennedy S, Lenhart G. Burden of illness in Parkin-son's disease. Mov Disord. 2005;20(11):1449-54.

Lau LM, Giesbergen PC, Rijk MC, Hofman A, Koudstaal PJ, Breteler MM. Incidence of parkinsonism and Parkinson disease in a general population: The Rotterdam Study. Neurology. 2004;63:1240-4.

Leon JB, Pareja FB, Gonzalez JM, Etessam JP, Trincado R, Vega S. Incidence of Parkinson disease and parkinsonism in three elderly populations of central Spain. Neurology. 2004;62:734-41.

Baldereschi M, Carlo DA, Rocca WA, Vanni P, Maggi S, Perissinotto E. Parkinson's disease and parkinsonism in a longitudinal study: Two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology. 2000;55:1358-63.

Priyadarshi A, Khuder SA, Schaub EA, Priyadarshi SS. Environmental risk factors and Parkinson's disease: A meta analysis. Environ Res. 2001;86:122-7.

Streifler M, Hofman S. Disorders of verbal expression in Parkinsonism. Adv Neurol. 1984;40:385-93.

Sachin S, Kumaran SS, Singh S, Goyal V, Shukla G, Mahajan H. Functional mapping in PD and PSP for sustained phonation and phoneme tasks. J Neurol Sci. 2008;273:51-6.

Cooper JA, Sagar HJ, Jordan N, Harvey NS, Sullivan EV. Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability. Brain. 1991;114(5):2095-122.

Sabate M, Rodriguez M, Mendez E, Enriquez E, Gonzalez I. Obstructive and restrictive pulmonary dysfunction increases disability in Parkinson disease. Arch Phys Med Rehabil. 1996;77:29-34.

Magalhaes M, Wenning GK, Daniel SE, Quinn NP. Autonomic dysfunction in pathologically confirmed multiple system atrophy and idiopathic Parkinson's disease--a retrospective comparison. Acta Neurol Scand. 1995;91:98-102.

Mesec A, Sega S, Trost M, Pogacnik T. The deterioration of cardiovascular reflexes in Parkinson's disease. Acta Neurol Scand. 1999;100:296-9.

Sriranjini SJ, Ganesan M, Datta K, Pal PK, Sathyaprabha TN. Effect of a single dose of standard levodopa on cardiac autonomic function in Parkinson's disease. Neurol India. 2011;59:659-63.

Blandini F, Nappi G, Tassorelli C, Martignoni E. Functional changes of the basal ganglia circuitry in Parkinson's disease. Prog Neurobiol. 2000;62:63-88.

Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson's disease: Loss of dopamine and noradrenaline innervation in the limbic system. Brain. 2005;128(6):1314-22.

Schrag A. Quality of life and depression in Parkinson's disease. J Neurol Sci. 2006;248(1-2):151-7.

Breen DP, Michell AW, Barker RA. Parkinson's disease-the continuing search for biomarkers. Clin Chem Lab Med. 2011;49(3):393-401.

Pahwa R, Lyons KE. Early diagnosis of Parkinson's disease: recommendations from diagnostic clinical guidelines. Am J Manag Care. 2010;16(9):94-9.

Dahodwala N, Willis AW, Li P, Doshi JA. Prevalence and correlates of anti-Parkinson drug use in a nationally representative sample. Mov Disord Clin Pract. 2017;4:335-41.

Alba MJE, Torres CLF, Mendoza GA, Spitia CJD. Prescribing patterns of antiparkinson drugs in a group of Colombian patients, 2015. Biomedica. 2018;38:417-26.